<DOC>
	<DOCNO>NCT00783263</DOCNO>
	<brief_summary>A study evaluate low-density lipoprotein cholesterol ( LDL-C ) lower efficacy addition ezetimibe rosuvastatin compare double dose rosuvastatin participant treat rosuvastatin alone National Cholesterol Education Program Adult Treatment Panel III ( NCEP ATP III ) LDL-C goal</brief_summary>
	<brief_title>A Study Ezetimibe Added On Rosuvastatin Versus Up Titration Rosuvastatin Patients With Hypercholesterolemia ( MK0653-139 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Participant currently take stable dose lipid lower agent ( ) . ( applicable ) statin naive Participant currently take stable dose lipid lower agent ( ) . ( least moderate high risk Coronary Heart Disease ( CHD ) ) Participant currently take stable dose lipid lower agent ( ) . ( willing maintain Therapeutic Lifestyle Changes ( TLC ) / American Diabetes Association ( ADA ) diet ) Participant weigh less 100 lb ( 45 kg ) . Participant hypersensitivity intolerance ezetimibe , rosuvastatin component medication . If female , participant pregnant breastfeeding . Participant consume 2 alcoholic beverage per day . Participant clinical trial within last 30 day . Participant heart problem CHF , unstable angina heart attack . Participant type 1 2 diabetes change medication last 2 month . Participant liver disease . Participant Human Immunodeficiency Virus ( HIV ) positive . Participant history drug alcohol abuse last year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>